NCT01964144View on ClinicalTrials.gov

An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Thyroid Cancer
Interventions
DRUG

Dovitinib

Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest

Trial Locations (1)

120-752

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01964144 - An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer | Biotech Hunter | Biotech Hunter